LCM
NAGE

Laurion Capital Management’s Niagen Bioscience NAGE Stock Holding History

Laurion Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-70,667
Closed -$297K – 1636
2018
Q1 		$297K Buy
+70,667
New +$370K ﹤0.01% 1136

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Laurion Capital Management's NAGE Position: Q2 2018 in Review

Laurion Capital Management sold out of Niagen Bioscience (NAGE) in Q2 2018, closing a stake of 70,667 shares — an estimated $297K sold.

Laurion Capital Management first reported a position in NAGE in Q1 2018 and held it in 1 quarter. The position peaked at $297K in Q1 2018. 64 funds tracked by Wall St. Rank hold NAGE as of Q2 2018.

  • Laurion Capital Management reported no remaining Niagen Bioscience position as of Q2 2018 after selling out during the quarter.
  • Laurion Capital Management sold 70,667 Niagen Bioscience shares in Q2 2018, an estimated $297K.
  • Laurion Capital Management first reported a position in Niagen Bioscience in Q1 2018 and held it in 1 quarter.
  • Laurion Capital Management's Niagen Bioscience position peaked at $297K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2018.

Based on Laurion Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.